Avalo Therapeutics Inc
Change company Symbol lookup
Select an option...
AVTX Avalo Therapeutics Inc
EWA iShares MSCI Australia ETF
WDAY Workday Inc
BNOX Bionomics Ltd
NRDY Nerdy Inc
KEY KeyCorp
AMPX Amprius Technologies Inc
TPC Tutor Perini Corp
LTRN Lantern Pharma Inc
JGGC Jaguar Global Growth Corporation I

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Growth
Company profile

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the treatment of immune dysregulation by developing therapies that target the Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT)-signaling network. Its clinical-stage pipeline includes AVTX-002, AVTX-008, and AVTX-803 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, Crohn’s Disease, and COVID-19 acute respiratory distress syndromes. AVTX-008 is a fully human B and T lymphocyte attenuator (BTLA) agonist fusion protein that is being evaluated for several immune dysregulation disorders. AVTX-803 is a monosaccharide therapy for the treatment of leukocyte adhesion deficiency type II (LAD II), which is a congenital disorder of glycosylation (CDG).

Closing Price
Day's Change
-0.028 (-16.53%)
B/A Size
Day's High
Day's Low

10-day average volume:

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.